Literature DB >> 33490069

Human Cancer Cells Sense Cytosolic Nucleic Acids Through the RIG-I-MAVS Pathway and cGAS-STING Pathway.

Yuan Qiao1, Shan Zhu1, Shuanglin Deng2, Shan-Shan Zou1, Bao Gao1, Guoxia Zang1, Jing Wu1, Yuxue Jiang1, Yong-Jun Liu3, Jingtao Chen1,4.   

Abstract

Pattern recognition receptors (PRRs) are germline-encoded host sensors of the innate immune system. Some human cancer cells have been reported to express PRRs. However, nucleic acid sensors in human cancers have not been studied in detail. Therefore, we systematically analyzed the expression, molecular cascade, and functions of TLR3, RIG-I, MDA5, LGP2, cGAS, and STING in human cancer cells. TLR3, TRIF, RIG-I, MDA5, LGP2, and MAVS were expressed in 22 cell lines. The majority of cell lines responded to only RIG-I ligands 5'-ppp-dsRNA, Poly(I:C)-HMW, Poly(I:C)-LMW, and/or Poly(dA:dT), as revealed by IRF3 phosphorylation and IFN-β secretion. IFN-β secretion was inhibited by RIG-I and MAVS knockdown. cGAS and STING were co-expressed in 10 of 22 cell lines, but IFN-β secretion was not induced by STING ligands ISD, HSV60, VACV70, Poly(dG:dC), and 3'3'-cGAMP in cGAS and STING intact cell lines. Further experiments revealed that the cGAS-STING pathway was activated, as revealed by TBK1 and IRF3 phosphorylation and IFN-β and ISG mRNA expression. These results suggest that human epithelial cancer cells respond to cytosolic RNA through the RIG-I-MAVS pathway but only sense cytosolic DNA through the cGAS-STING pathway. These findings are relevant for cancer immunotherapy approaches based on targeting nucleic acid receptors.
Copyright © 2021 Qiao, Zhu, Deng, Zou, Gao, Zang, Wu, Jiang, Liu and Chen.

Entities:  

Keywords:  IFN-β; RIG-I; STING; cancer cell; nucleic acid

Year:  2021        PMID: 33490069      PMCID: PMC7820189          DOI: 10.3389/fcell.2020.606001

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  38 in total

1.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors:  Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

2.  RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium.

Authors:  Alexis H Broquet; Yoshihiro Hirata; Christopher S McAllister; Martin F Kagnoff
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 3.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

Review 4.  Mechanisms and pathways of innate immune activation and regulation in health and cancer.

Authors:  Jun Cui; Yongjun Chen; Helen Y Wang; Rong-Fu Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization.

Authors:  Xin Li; Chang Shu; Guanghui Yi; Catherine T Chaton; Catherine L Shelton; Jiasheng Diao; Xiaobing Zuo; C Cheng Kao; Andrew B Herr; Pingwei Li
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

6.  The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells.

Authors:  Samantha S W Ho; Wendy Y L Zhang; Nikki Yi Jie Tan; Muznah Khatoo; Manuel A Suter; Shubhita Tripathi; Florence S G Cheung; Weng Khong Lim; Puay Hoon Tan; Joanne Ngeow; Stephan Gasser
Journal:  Immunity       Date:  2016-05-10       Impact factor: 31.745

Review 7.  Viral RNA detection by RIG-I-like receptors.

Authors:  Mitsutoshi Yoneyama; Koji Onomoto; Michihiko Jogi; Teppei Akaboshi; Takashi Fujita
Journal:  Curr Opin Immunol       Date:  2015-01-14       Impact factor: 7.486

8.  IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.

Authors:  Taro Kawai; Ken Takahashi; Shintaro Sato; Cevayir Coban; Himanshu Kumar; Hiroki Kato; Ken J Ishii; Osamu Takeuchi; Shizuo Akira
Journal:  Nat Immunol       Date:  2005-08-28       Impact factor: 25.606

9.  Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3.

Authors:  Rashu B Seth; Lijun Sun; Chee-Kwee Ea; Zhijian J Chen
Journal:  Cell       Date:  2005-09-09       Impact factor: 41.582

Review 10.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases.

Authors:  Michel Gilliet; Wei Cao; Yong-Jun Liu
Journal:  Nat Rev Immunol       Date:  2008-08       Impact factor: 53.106

View more
  5 in total

Review 1.  Programmed death ligand 1 signals in cancer cells.

Authors:  Anand V R Kornepati; Ratna K Vadlamudi; Tyler J Curiel
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 60.716

2.  A genetic screen identifies a protective type III interferon response to Cryptosporidium that requires TLR3 dependent recognition.

Authors:  Alexis R Gibson; Adam Sateriale; Jennifer E Dumaine; Julie B Engiles; Ryan D Pardy; Jodi A Gullicksrud; Keenan M O'Dea; John G Doench; Daniel P Beiting; Christopher A Hunter; Boris Striepen
Journal:  PLoS Pathog       Date:  2022-05-18       Impact factor: 7.464

3.  Protocol to induce and assess cGAS-STING pathway activation in vitro.

Authors:  Hanane Chamma; Soumyabrata Guha; Nadine Laguette; Isabelle K Vila
Journal:  STAR Protoc       Date:  2022-05-14

4.  Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells.

Authors:  Ruben Serrano; Marcus Lettau; Michal Zarobkiewicz; Daniela Wesch; Christian Peters; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2022-02-01       Impact factor: 8.110

Review 5.  Emerging role of RNA sensors in tumor microenvironment and immunotherapy.

Authors:  Rui Yang; Sihui Yu; Tianhan Xu; Jiawen Zhang; Sufang Wu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.